Date: 2015-04-06
Type of information: Financing round
Company: Intercept Pharmaceuticals (USA - NY)
Investors:
Amount: $366.8 million
Funding type: financing round
Planned used:
Others: * On April 6, 2015, Intercept Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, announced the completion of its previously announced underwritten public offering of 1,200,000 shares of its common stock. In addition, Intercept announced the completion of the sale of an additional 130,865 shares of its common stock pursuant to the partial exercise of the underwriters\' option to purchase additional shares. All shares in the offering were sold by Intercept to the underwriters at a price of $276.00 per share. Net proceeds to Intercept from the sale of 1,330,865 shares of its common stock in the offering are expected to be approximately $366.8 million, after deducting estimated offering expenses. UBS Investment Bank and Citigroup acted as underwriters in the offering. * On March 31, 2015, Intercept Pharmaceuticals announced the pricing of an underwritten public offering of 1,200,000 shares of its common stock. The underwriters intend to offer the shares of common stock from time to time for sale in one or more transactions on The Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Intercept granted the underwriters 30-day option to purchase up to an additional 180,000 shares of common stock, on the same terms and conditions. All shares in the offering are being sold by Intercept, with estimated total gross proceeds to Intercept (before deducting underwriters\' discounts and commissions and estimated offering expenses) of approximately $338.4 million (or approximately $389.2 million if the underwriters exercise in full their option to purchase additional shares). The offering is expected to close on or about April 6, 2015, subject to customary closing conditions.
Therapeutic area:
